$荃信生物-B(02_老虎社区_美港股上老虎

$荃信生物-B(02509)$ 荃信QX002N是一种IL-17A抑制剂，2025年2月QX002N于中国针对强直性脊柱炎(AS) 的III期临床试验已达到主要终点

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":439570170106192,"tweetId":"439570170106192","gmtCreate":1748335796612,"gmtModify":1748335797881,"author":{"id":4136460772891970,"idStr":"4136460772891970","authorId":4136460772891970,"authorIdStr":"4136460772891970","name":"牛熊两吃","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$</a> 荃信QX002N是一种IL-17A抑制剂，2025年2月QX002N于中国针对强直性脊柱炎(AS) 的III期临床试验已达到主要终点</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02509\">$荃信生物-B(02509)$</a> 荃信QX002N是一种IL-17A抑制剂，2025年2月QX002N于中国针对强直性脊柱炎(AS) 的III期临床试验已达到主要终点</p></body></html>","text":"$荃信生物-B(02509)$ 荃信QX002N是一种IL-17A抑制剂，2025年2月QX002N于中国针对强直性脊柱炎(AS) 的III期临床试验已达到主要终点","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/439570170106192","repostId":0,"isVote":1,"tweetType":1,"viewCount":95,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02509"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":118,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/439570170106192"}